Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 2/20 | 0.55 |
| ▸ | ALOX5 | P09917 | 3/20 | 0.49 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.49 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.48 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | MIF | P14174 | 1/20 | 0.48 |
| ▸ | TYR | P14679 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 5/20 | 0.44 |
| ▸ | HDAC2 | Q92769 | 5/20 | 0.44 |
| ▸ | RARB | P10826 | 1/20 | 0.44 |
| ▸ | RARG | P13631 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7057689 | 0.86 | CA2 (0.57) | ERN1ALOX5PTGS1PTGS2ALDH1A1 | |
| SCHEMBL6068103 | 0.80 | ERN1 (0.64) | ERN1ALOX5KCNH2HDAC1HDAC2 | |
| SCHEMBL29744559 | 0.80 | ERN1 (0.64) | ERN1ALOX5KCNH2HDAC1HDAC2 | |
| SCHEMBL278760 | 0.79 | KCNH2 (0.66) | ALOX5PTGS1PTGS2KCNH2HDAC1 | |
| SCHEMBL1176397 | 0.79 | ALDH1A1 (0.67) | ALDH1A1ALOX15NR1I2LMNACYP2C9 | |
| SCHEMBL31146788 | 0.79 | ALDH1A1 (0.67) | ALDH1A1ALOX15NR1I2LMNACYP2C9 | |
| SCHEMBL18646041 | 0.79 | CYP1A2 (0.61) | ERN1ALOX5PTGS1PTGS2ALDH1A1 | |
| SCHEMBL172744 | 0.79 | ERN1 (0.58) | ERN1KCNH2HDAC1HDAC2HDAC3 | |
| SCHEMBL17049365 | 0.78 | ERN1 (0.62) | ERN1ALDH1A1KCNH2HDAC1HDAC2 | |
| SCHEMBL19317253 | 0.77 | KCNH2 (0.49) | ERN1ALOX5PTGS1PTGS2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8431610-B2 | Alkanoylamino benzamide aniline HDAC inhibitor compounds | GILEAD SCIENCES, INC. (US) | 2013-04-30 | — | — | US | disclosed |
| US-20120301426-A1 | ALKANOYLAMINO BENZAMIDE ANILINE HDAC INHIBITOR COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2012-11-29 | — | — | US | disclosed |
| US-8283357-B2 | Cycloalkylcarbamate benzamide aniline HDAC inhibitor compounds | GILEAD SCIENCES, INC. (US) | 2012-10-09 | — | — | US | disclosed |
| US-8283357-B2 | Cycloalkylcarbamate benzamide aniline HDAC inhibitor compounds | GILEAD SCIENCES, INC. (US) | 2012-10-09 | — | — | US | disclosed |
| US-8258316-B2 | Alkanoylamino benzamide aniline HDAC inhibitor compounds | GILEAD SCIENCES, INC. (US) | 2012-09-04 | — | — | US | disclosed |
| US-20100311794-A1 | CYCLOALKYLCARBAMATE BENZAMIDE ANILINE HDAC INHIBITOR COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2010-12-09 | — | — | US | disclosed |
| US-20100311794-A1 | CYCLOALKYLCARBAMATE BENZAMIDE ANILINE HDAC INHIBITOR COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2010-12-09 | — | — | US | disclosed |
| US-20100310500-A1 | ALKANOYLAMINO BENZAMIDE ANILINE HDAC INHIBITOR COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2010-12-09 | — | — | US | disclosed |
| US-20100310500-A1 | ALKANOYLAMINO BENZAMIDE ANILINE HDAC INHIBITOR COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2010-12-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100310500-A1 | ALKANOYLAMINO BENZAMIDE ANILINE HDAC INHIBITOR COMPOUNDS | HDAC1, HDAC5, HDAC7 | ERN1 2623/4885ALOX5 2845/4885PTGS1 3041/4885 |
| US-20120301426-A1 | ALKANOYLAMINO BENZAMIDE ANILINE HDAC INHIBITOR COMPOUNDS | HDAC1, HDAC5, HDAC7 | ERN1 2623/4885ALOX5 2845/4885PTGS1 3041/4885 |
| US-20100311794-A1 | CYCLOALKYLCARBAMATE BENZAMIDE ANILINE HDAC INHIBITOR COMPOUNDS | HDAC1, HDAC5, HDAC3 | ERN1 3796/4885ALOX5 2822/4885PTGS1 2540/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.